How to Get Ozempic Online in 2026
Ozempic (semaglutide) is FDA-approved for type 2 diabetes management. Telehealth providers can prescribe Ozempic for on-label use; many also offer compounded semaglutide as a weight-loss alternative.
Ozempic is a once-weekly semaglutide injection FDA-approved for type 2 diabetes in adults.
Adults with type 2 diabetes seeking glycemic control and the cardiovascular benefits documented in the SUSTAIN trials.
Pen-injector format. Monthly cost without insurance typically $850-$1,000.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
Providers That Prescribe Ozempic
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Board-certified primary-care telehealth with the widest brand-name GLP-1 access in this list.
Full-spectrum GLP-1 program with both compounded and brand-name access plus unlimited provider check-ins.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Personalised, physician-endorsed longevity and weight-loss therapies, fully online.
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Cash-pay telehealth marketplace with transparent per-visit pricing and Costco-member discounts.
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Wide compounded and brand-name catalog covering weight loss, anti-aging, and hair growth without insurance.
Personalised GLP-1 and sexual-wellness program with insurance navigation and optional nutrition coaching.
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
Medically supervised, discreet, multi-category telehealth with a heavy compounded formulary.
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
What the Studies Actually Show
Ozempic is FDA-approved semaglutide for type 2 diabetes. The figures below come from the SUSTAIN program (registration trials) and SELECT (cardiovascular outcomes), and from the FDA prescribing information.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Boxed warning3 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SUSTAIN program)4 | ≈1.4–1.8% A1C reduction at 1.0 mg weekly across SUSTAIN-2 through SUSTAIN-7 head-to-head trials |
| Compounded semaglutide — evidence basis5 | Active ingredient is identical to Wegovy/Ozempic; efficacy is inferred from the active ingredient. The FDA does not formally approve compounded products; quality depends on the 503A/503B compounding pharmacy Following the FDA's 2024 ruling that ended the official tirzepatide and semaglutide shortages, compounded GLP-1s are dispensed under the personalisation exception, which requires a documented clinical justification (custom dose, B12 addition, or documented intolerance to an inactive ingredient). |
Frequently Asked Questions
Can I get Ozempic for weight loss?
Ozempic is FDA-approved only for type 2 diabetes. For weight loss, the same active ingredient is FDA-approved as Wegovy.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- FDA Prescribing Information — Wegovy (semaglutide) · WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SUSTAIN program — ADA scientific summary · Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 clinical trials. Diabetes Obes Metab 2019;21(7):1601–1613.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.